Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 9 May 2019, 11:33 HKT/SGT
Share:
    

Source: Eisai
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions

TOKYO, May 9, 2019 - (JCN Newswire) - Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care. Under this capital and business alliance, the two companies will collaborate on information provision to patients and healthcare professionals as well as development and provision of digital health solutions in regional medical treatment cooperation and comprehensive community care by extensively utilizing Allm's ICT systems for medical treatment and care. By applying Allm's experience in medical ICT systems to the "Dementia Ecosystem" that Eisai aims to establish, the two companies will thoroughly promote the utilization of IoT, big data and AI technologies in the health care area and provide new value for patients under the Fourth Industrial Revolution.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), promoting various kinds of digitalization such as the analysis of big data including real world data for the development of diagnostic methods and the provision of solutions in addition to creating next-generation treatment primarily in "neurology" and "oncology" that are Eisai's therapeutic areas of focus. Especially in the area of dementia, Eisai aims to establish the "Eisai Dementia Platform" by actively utilizing external big data and genomic data in addition to Eisai's own experience, know-how, and clinical data as well as build the "Dementia Ecosystem" by collaborating with partners such as other pharmaceutical companies, governments, medical organizations, care facilities, diagnostic developing companies, IT companies and insurance companies. Eisai thus aims to deliver novel benefits to patients with dementia and their families.

As "a company supporting all medicines (All Medical)", Allm upholds "Shaping Healthcare" as its corporate message, and provides services making contributions to the creation of global, social welfare design through IT technology. As a venture company specialized in medicine and healthcare, Allm is engaged in the development of programs for medical devices and provides "Team" comprehensive community care application and "MySOS" personal health record app. Currently operating in 12 countries, the company internationally provides approximately 1,700 medical/nursing institutions with ICT systems for medicine and nursing. In particular, the "Join" communication app for communication among healthcare professionals has become Japan's first medical device program which was made eligible for national health insurance by the Central Social Insurance Medical Council of the Japanese Ministry of Heath, Labor and Welfare.

Through these efforts to coordinate on the provision of healthcare solutions using ICT and the establishment of ecosystems in the area of dementia and others, Eisai and Allm are working to solve issues in regional medical treatment and care, and therefore contribution to the realization of well-being.

About Allm Inc.

As a "company supporting all medicines (All Medical)" upholding "Shaping Healthcare" as its corporate message, Allm provides mobile ICT solutions in the area of medicine and welfare. The company also proactively approaches global deployment of medical ICT business including the "Join" app for communication among healthcare professionals, providing solutions in 12 countries as a Japanese medical ICT company.

For more information about Allm Inc., please visit https://www.allm.net.


Contact:
Allm Inc.
Group Strategy Office 
Tel:03-6418-3010

Eisai Co., Ltd.
Public Relations Department 
Tel:03-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: